On Monday, Tempus AI hit a noteworthy performance benchmark, with its Relative Strength (RS) Rating jumping into the 90-plus percentile with an improvement to 92, an increase from 88 the day before.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an 80 or better RS Rating in the early stages of their moves.
While Tempus AI is not near an ideal buying range right now, see if it goes on to form and break out from a proper base.
Tempus AI reported 0% earnings growth last quarter, while sales growth came in at 36%. The next quarterly numbers are expected on or around May 6.
The company earns the No. 3 rank among its peers in the Medical-Research Equipment/Services industry group. Tempus AI is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
